

Corrigendum

**Corrigendum to “Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)”**

[*Bioorg. Med. Chem. Lett.* 13 (2003) 4355]<sup>☆</sup>

Juswinder Singh,<sup>\*</sup> Claudio E. Chuaqui, P. Ann Boriack-Sjodin, Wen-Cherng Lee, Timothy Pontz, Michael J. Corbley, H.-Kam Cheung, Robert M. Arduini, Jonathan N. Mead, Miki N. Newman, James L. Papadatos, Scott Bowes, Serene Josiah and Leona E. Ling

*Biogen Inc., Structural Informatics Group, 14 Cambridge Center, Cambridge, MA 01242, USA*

The authors wish to add a reference to the parallel discovery of 4-(3-pyridin-2-yl-1*H*-pyrazol-4-yl)-quinoline (HTS466284) using high-throughput screening which supports the utility of both HTS and virtual screening in drug discovery.<sup>1</sup>

**References and notes**

1. Sawyer, J. S.; Anderson, B. D.; Beight, D. W.; Campbell, R. M.; Jones, M. L.; Herron, D. K.; Lampe, J. W.; McCowan, J. R.; McMillen, W. T.; Mort, N.; Parsons, S.; Smith, E. C. R.; Vieth, M.; Weir, L. C.; Yan, L.; Zhang, F.; Yingling, J. M. *J. Med. Chem. (Lett.)* **2003**, *46*, 3953–3956.

<sup>☆</sup> DOI of original article 10.1016/j.bmcl.2003.09.028

<sup>\*</sup> Corresponding author. Tel.: +1-617-679-2000; fax: +1-617-679-2617; e-mail: [juswinder\\_singh@biogen.com](mailto:juswinder_singh@biogen.com)